Previous 10 | Next 10 |
March 14, 2019 Palm Beach, FL – March 14, 2019 – According to the Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are an estimat...
HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the first patients have been treated in the...
Akari Therapeutics (NASDAQ: AKTX ) +19% on announcing that it had a successful Type B, pre-IND meeting with the FDA. More news on: Akari Therapeutics, Plc, Pareteum Corporation, PAVmed Inc., Stocks on the move, Read more ...
March 13, 2019 Palm Beach, FL – March 13, 2019 – Cancer research has for years been steadily gaining ground on its way to managing, curing and even preventing the various forms of this insidious disease. Both public and private money continues to flow into the hands of rese...
HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has submitted a request for Fast Tr...
Moleculin Biotech (NASDAQ: MBRX ): FY GAAP EPS of -$0.46 beats by $0.01. More news on: Moleculin Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas Syst...
Moleculin Biotech (NASDAQ: MBRX ) has entered into a sublicense agreement with WPD Pharmaceuticals (WPD), located in Poland. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System...
VANCOUVER, British Columbia , Feb. 19, 2019 /PRNewswire/ -- Weekend Unlimited Inc. ("Weekend" or the "Company") (CSE: POT ) (FSE: 0OS1) (OTCMKTS: WKULF) is pleased to announce that Northern Lights Supply in Nisku, Alberta has received its initial shipment from AGLC allowing...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $109.21 on volume of 508,402,989 shares Redhill Biopharma Ltd. (RDHL) rose 97.9% to $0.76 on volume of 355,380,053 shares PROSHARES TRUST (SQQQ) rose 7.3% to $9.22 on volume of 284,777,109 shares ...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...